Dcgi
-
COVID-19 vaccines in India: In a nutshell
India | April 13, 2021 22:21 ISTThe Drugs Control General of India has permitted emergency use of Covid vaccine Sputnik V with certain conditions, clearing the way for a third vaccine in addition to Covishield and Covaxin.
-
Would make every Indian proud: PM Modi on DCGI's final approval to Covishield, Covaxin
India | January 03, 2021 12:08 ISTCovid-19 vaccines- COVAXIN and COVISHIELD have been cleared for restricted use in emergency situation, DCGI, V G Somani said.
-
Covishield, Covaxin get govt's nod: DCGI's Full Statement
India | January 03, 2021 12:07 ISTThe expert panel has recommended granting permission for restricted emergency use of 'Covaxin' in "public interest as an abundant precaution, in clinical trial mode, especially in the context of infection by mutant strains.
-
Will India get Covid vaccines on Sunday? DCGI BIG announcement expected
News | January 02, 2021 22:24 ISTThe Drug Controller General of India (DCGI) will address a press conference on Sunday (January 3) at 11 am and it is being expected that the drug controller watchdog may announce the approval of emergency use of two vaccines.
-
Will India get Covid vaccines today? DCGI BIG announcement expected
India | January 03, 2021 8:21 ISTThe Drug Controller General of India (DCGI) will address a press conference today at 11 am and it is being expected that the drug controller watchdog may announce the approval of emergency use of two vaccines. The development comes after the government panels recommended — Oxford-AstraZeneca Covishield and Bharat Biotech's Covaxin — for emergency use.
-
Oxford-AstraZeneca COVID-19 vaccine gets recommendation for emergency use
India | January 01, 2021 23:28 ISTAn expert panel on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) on Friday recommended to grant emergency use authorisation for the Oxford COVID-19 vaccine Covishield, being manufactured by Serum Institute of India, sources said on Friday.
-
Oxford COVID-19 vaccine may become the first to get Indian regulator's nod for emergency use
India | December 26, 2020 17:58 ISTWith preparations underway for a possible vaccine-rollout by January, the Indian drug regulator is looking at the UK, which sources believe may give its nod to the Oxford COVID-19 vaccine next week, before deciding on giving emergency use authorisation to the Serum Institute that is manufacturing the shots here.
-
Covid cases in India rise, Bharat Biotech's vaccine begins phase 3 trial
News | November 27, 2020 10:00 ISTThe vaccine 'Covaxin' is being indigenously developed by the Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
-
Sputnik V, Russia's coronavirus vaccine, gets nod for clinical trials in India
India | October 17, 2020 17:27 ISTThe Drug Controller General of India (DCGI) has granted approval to Dr Reddy's, a global pharmaceutical company headquartered in India, to conduct phase 2 and 3 clinical human trials of the Sputnik V, a Covid-19 vaccine made by Russia.
-
DCGI approves commercial launch of low cost COVID-19 test 'Feluda'
India | September 20, 2020 8:31 ISTThe Drugs Controller General of India has approved the commercial launch of 'Feluda', the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) COVID-19 test, the Council of Scientific and Industrial Research (CSIR) said on Saturday.
-
Serum Institute gets DCGI nod to resume Oxford COVID vaccine's clinical trial
India | September 16, 2020 9:41 ISTDrugs Controller General of India (DCGI) Dr VG Somani on Tuesday gave permission to Serum Institute of India to resume the clinical trial of the Oxford COVID-19 vaccine candidate in the country while revoking its earlier order of suspending any new recruitment for phase two and three trial.
-
Serum Institute gets DCGI notice for not informing AstraZeneca pausing vaccine trials abroad
India | September 09, 2020 23:26 ISTThe Serum Institute of India (SII), which is conducting Oxford-AstraZeneca coronavirus vaccine phase 2 and 3 trials in India, has received a show-cause notice from the central drug regulator for not informing it about pharma giant AstraZeneca pausing the clinical trials of the Oxford vaccine candidate in other countries and also for not submitting casualty analysis of the "reported serious adverse events".
-
Zenara Pharma receives DCGI approval to manufacture, sell Favipiravir tablets
Business | August 05, 2020 16:32 ISTThe tablet, which will be sold under the brand name 'Favizen', is being manufactured at Zenar's US FDA approved facility in Hyderabad, a press release from the drug maker said.
-
Serum Institute gets nod to conduct Oxford's coronavirus vaccine Phase 2, 3 human trials in India
Good News | August 03, 2020 8:15 ISTSerum Institute of India (SII) has been granted permission by Drugs Controller of General of India (DCGI) to conduct Phase 2, 3 human trials of Oxford-AstraZeneca coronavirus vaccine in India, a government official has said.
-
Biocon drug receives DCGI nod for use in moderate to severe COVID-19 patients
Business | July 11, 2020 17:22 ISTBiotechnology major Biocon on Saturday announced that its "breakthrough drug," Itolizumab has received Drugs Controller General of India's (DCGI) approval for its use in moderate to severe COVID-19 patients.
-
DCGI asks manufacturers to take steps to prevent black-marketing, overpricing of COVID-19 drugs
India | July 10, 2020 7:07 ISTRajesh Bhushan, the Officer on Special Duty, Union Health Ministry, told an online media briefing Thursday that it has been noticed that certain drugs are not available freely in the market.
-
DCGI approves clinical trials of Favipiravir used in influenza in Japan, China for COVID-19: CISR DG
News | May 08, 2020 20:23 ISTThe Certified Insurance Service Representative (CISR) Director General Dr. Shekhar C. Mande while talking about drugs that can be useful against COVID-19 informed that the Drug Controller General of India has given approval for clinical trials of Favipiravir which is used in influenza in Japan, China etc.
-
Regulator detects issues in Combiflam, Sanofi withdraws batches
May 12, 2016 17:36 ISTNew Delhi: Sanofi has withdrawn some batches of its popular painkiller Combiflam after the Drugs Controller General of India (DCGI) found the drug to be of sub-standard quality. According to a DCGI alert, the sub-standard
-
Post stringent norms, clinical trials in India plummet
India | April 21, 2013 16:33 ISTNew Delhi, Apr 21: Clinical trials of drugs in India have seen a drastic fall this year after toughened norms were introduced following Supreme Court directives.Not only have the number of trial approvals in the
Top News
-
Seven killed, 15 injured as bus collides with truck on Delhi-Mumbai Expressway in Rajasthan
-
Will Supersonic Flights return to US skies? Why America is moving to lift a 53-year-old flight ban
-
Mumbai rains LIVE Updates: Waterlogging reported in many parts, IMD predicts heavy rains till July 4
-
Nayara Energy cuts petrol, diesel prices as crude oil remains stable, check new rates in your city
Latest News
-
Pet dog gives its life fighting black cobra to protect family in Haryana's Karnal
-
Why UK roads melt at 40 degrees Celsius but the ones in India survive harsher summer heat
-
Vijaya Mehta, Marathi theatre legend, dies at 92; Anupam Kher offers condolences
-
Nayara Energy cuts petrol, diesel prices as crude oil remains stable, check new rates in your city
-
Car gets stuck on steep hairpin bend in Uttarakhand | Watch viral video
-
Pet dog gives its life fighting black cobra to protect family in Haryana's Karnal
-
Car gets stuck on steep hairpin bend in Uttarakhand | Watch viral video
-
Employee quits after wedding leave is denied. The last line of his resignation email says it all
-
US woman finds herself stranded after her phone dies in Delhi. What happened next left her moved
-
'Life just isn't getting set anymore': Man's post on modern jobs strikes a chord online